Tumour necrosis factor-α inhibitors, immune-mediated inflammatory diseases, and bloodstream infections: results from a nationwide case-control study
TNFi use is associated with increased odds of BSIs and was observed across the most frequent species. Odds varied by TNFi type and underlying disease, with the highest odds among patients with inflammatory bowel disease, emphasizing the need for individualized infection risk assessment.
Authors
- Jon Gitz Holler (ORCID: https://orcid.org/0000-0001-6101-6821)
- Alessandra Meddis (ORCID: https://orcid.org/0000-0002-0520-0701)
- Johan Burisch
- Tue Wenzel Kragstrup
- Lone Skov
- Thomas Benfield
- Cæcilie Leding
Institutions
- University of Copenhagen (DK)
- Amager Hospital (DK)
- Hvidovre Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Zealand University Hospital (DK)
Publication Details
- Journal
- Clinical Microbiology and Infection
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.cmi.2026.02.005
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00